Search:

Login | Subscribe

Home > Companies > Medical Marketing...

Price	Market	Sector	Market Cap
7.25p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£4.62m

Add to company folder | Print

Related Companies

AGY	10.00p	0.00%
APH	4.62p	0.00%
AZH	p
BBI	p
CEN	p
CBF	2.00p	0.00%
COT	91.50p	-0.54%
CRX	2.62p	0.00%
CYX	p
LAC	p
EVC	25.75p	0.00%
FUL	3.12p	0.00%
FUM	27.25p	-0.91%
GMX	1.75p	0.00%
GNI	p
GWP	29.50p	-0.84%
HML	0.42p	0.00%
MLR	p
MPM	9.75p	5.41%

Commentary

Pharmaceutical development company focused on drugs for the treatment of cancer and infectious diseases

Recent Articles

MMI bullish after interim loss	27/11/2007
Aim Report	01/07/2003
Medical Marketing International	09/08/2002
Best clinches 'brilliant deal'	18/02/2002
Medical Marketing International	18/02/2002
Medical Marketing International	19/04/2000
Medical Marketing International	01/01/2000
Medical Marketing International	01/10/1999

Recent Announcements

Conclusion of Annual General Meeting	04/12/2008
Investment in Genvax Limited	30/10/2008
Notification of Major Interest in Shares	13/10/2008
Response to press comments	10/10/2008
Divestment of subsidiary	30/09/2008
Result of AGM	17/09/2008
AGM Statement	17/09/2008
Notice of AGM	12/09/2008
Annual Information Update & A	14/08/2008
Holding(s) in Company	07/08/2008
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	31/03/2004	31/03/2005	31/03/2006	31/03/2007	31/03/2008
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	0.38	0.38	0.20	0.10	0.14
Operating Profit	-2.14	-1.77	-3.14	-4.27	-3.70
Pretax Profit	-2.12	-1.72	-2.93	-3.92	-3.46
Earnings After Tax	-2.12	-1.71	-2.77	-3.77	-3.46
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	-2.12	-1.71	-2.77	0.00	0.00
Shareholders Funds	3.05	3.59	10.74	7.71	4.41
Net Current Assets	1.34	1.81	9.10	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	0.00	-5.84	-5.59
Adj Earnings Per Share	0.00	0.00	0.00	-5.84	-5.59
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	The Bioscience Innovation Centre, Cowley Road, Cambridge, CB4 0DS
Telephone	01223 477 677
Fax	01223 477 678
Executives
Chairman	Phil Cartmell (0.00% holding)
Chief Executive	(0.00% holding)
Finance Director	Rob Sprawson (0.00% holding)
Medical Director	James Brenton (0.00% holding)
Main Shareholders
	Prudential: 20% David Best: 19.6% Margaret Mitchell: 10.4% Universities Superannuation Scheme: 6.4%
Advisers
Nominated Adviser	FinnCap
Nominated Broker	FinnCap
Solicitors	Eversheds
Auditors	KPMG
Registrar	Capita Registrars

Commentary
Pharmaceutical development company focused on drugs for the treatment of cancer and infectious diseases
Company Data
Code	MMG
Sedol	GB00041506
Shares In Issue	63.666 m
Indices	Aim
Entry on AIM	14/11/2000
Interim Results	Nov
Final Results	Jul
Year End	Mar
Accounts Due	Sep
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes